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A 32 year old male presented to our services with severe, progressive breathlessness. Following
a detailed clinical work-up he was found to have severe pulmonary arterial hypertension due to chronic
thromboembolic disease. No risk factor for venous thromboembolism,was identiﬁed at this time.
Vasculitic screen including anti-neutrophil cytoplasmic antibody (ANCA) was normal. He was referred for
pulmonary artery endarterectomy which was performed successfully and with good initial improvement
in his symptom complex. He represented with breathlessness four months later. He was diagnosed with
necrotizing granulomatous vasculitis (known formerly as Wegner's Granulomatosis). While an associa-
tion between necrotizing granulomatous vasculitis and venous thromboembolic disease is well
described, to our knowledge this is the ﬁrst case of a patient with chronic thromboembolic pulmonary
hypertensive disease subsequently developing fulminant necrotizing granulomatous vasculitis.
 2011 Elsevier Ltd. All rights reserved.To The Editors
While an association between necrotizing granulomatous
vasculitis and venous thromboembolic disease is well described,
we herein report case of a patient with chronic thromboembolic
pulmonary hypertensive disease subsequently developing fulmi-
nant necrotizing granulomatous vasculitis.
A 32-year-old caucasian male farmer was referred to our centre,
for investigation of progressive dyspnoea over 18 months. At
review he had New York Heart Association (NYHA) functional class
III-IV symptoms. He had a history of 2 previous pulmonary emboli
without any identiﬁable risk factor for venous thrombolism (VTE).
He was on lifelong warfarin, in accordance with international
guidelines.1 He was an ex-smoker, with a 12 pack year smoking
history. His physical examination was notable for resting oxygen
saturations of 96%, raised jugular venous pulse, loud second heart
sound and pulsatile liver edge. His lung ﬁelds were clear to
auscultation.
A transthoracic echo estimated his systolic pulmonary arterial
pressure at 60 mmHg. High resolution CT thorax demonstrated
mosaic attenuation pattern. A right heart catheterisation revealed
a mean pulmonary arterial pressure of 65 mmHg with a normal. Forde), mccullaghbrian@
.T. Henry), s.gaine@mater.ie
rved.pulmonary capillary wedge pressure. Notably, autoimmune screen,
ANCA and thrombophilia screen were all negative.
He underwent pulmonary angiography at the national pulmo-
nary hypertension unit which conﬁrmed evidence of proximal
thromboembolic disease. He was referred to the University of Cal-
fornia Medical Centre, San Diego for a pulmonary thromboendar-
terectomy and in the interim he was maintained on bosentan and
sildenaﬁl. His endarterectomy was performed successfully and at
initial review he had NYHA functional class II symptoms and was
contemplating a return to work.
Unfortunately, 4 months later he presented with low grade
fever, weight loss, non productive cough and malaise. A chest x-ray
demonstrated multiple cavities (Fig. 1). A CT thorax conﬁrmed the
presence of new pulmonary cavities and nodules bilaterally (Fig. 2).
His clinical work-up revealed c-ANCA positivity with an anti-
proteinase 3 titre of 245 U/mL (normal <10U/mL). Bronchial
lavage showed numerous haemosiderin-laden macrophages
suggestive of pulmonary haemorrhage. He was diagnosed with
necrotizing granulomatous vasculitis and commenced on steroids
and oral cyclophosphamide. He responded well for an initial 8
month period and indeed returned to work, but 13 months post
diagnosis, symptoms pertaining to pulmonary hypertension began
to return and he was commenced on treprostenil.
Pulmonary hypertension is deﬁned by a mean pulmonary
arterial pressure  25 mmHg at rest, with a pulmonary capillary
wedge pressure  15 mmHg assessed by right heart catheteriza-
tion. The new classiﬁcation of pulmonary hypertension divides the
Fig. 1. Chest X-Ray demonstrating nodules and cavities bilaterally, most prominent in
right lower zone.
Fig. 2. CT image conﬁrming the presence of multiple cavities and nodules seen on CXR.
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response, with chronic thromboembolic pulmonary hypertension
(CTEPH) placed in group 4. It occurs due to incomplete resolution of
pulmonary thrombi, which undergo organisation in the pulmonary
arteries with vascular remodelling and thromboendarterectomy,
where proximal organised thrombus is accessible to surgical
removal. There is some evidence to support the use of the endo-
thelin receptor antagonist bosentan in CTEPH, in those considered
inoperable or in an attempt to optimise pre-operative haemody-
namics, targetted pulmonary arterial hypertension drug therapy
may be considered.2,3
Necrotizing granulomatous vasculitis, is a small-medium vessel,
necrotizing vasculitis of undetermined etiology (previously
Wegner’s Granulomatosis).4 Clinical presentation varies fromlimited disease to a fulminant systemic disease. Diagnosis is often
difﬁcult and outcomes are variable.5
The risk of venous thromboembolism is increased in necrotizing
granulomatous vasculitis. In the WeCLOT study 16% of patients
demonstrated evidence of venous thromboembolism. This study
followed patients with active necrotizing granulomatous vasculitis,
looking for evidence of venous thromboembolism and found that
the incidence of venous thromboembolism among patients with
necrotizing granulomatous vasculitis was increased especially
during periods of active disease.6
Our patient’s presentation is unusual in that chronic thrombo-
embolic disease developed years prior to any evidence of systemic
vasculitis. At initial presentation we documented c-ANCA nega-
tivity. While c-ANCA negativity is reported in necrotizing granu-
lomatous vasculitis and c-ANCA levels are known to ﬂuctuate
without therapeutic intervention, we believe this would be atyp-
ical, especially in the absence of systemic disease (other than
perhaps VTE). Furthermore, our patient was c-ANCA positive at the
time he represented with systemic manifestations of necrotizing
granulomatous vasculitis suggesting that the disease represented
a new clinical entity. However, it remains impossible to say deﬁn-
itively that he did not have subclinical, c-ANCA negative vasculitis
from the start.
In summary, we present the unusual case of a man who devel-
oped severe pulmonary hypertension due to CTEPH who later
developed necrotizing granulomatous vasculitis. While necrotizing
granulomatous vasculitis has previously been associated with
increased risk of subsequent development of chronic thrombo-
embolic disease, this is, to our knowledge the ﬁrst case of a patient
developing the condition years following diagnosis, and indeed
attempted deﬁnitive management of chronic thromboembolic
disease.6 It is unknown whether the chronic thromboembolic
disease was an initial presenting feature of his necrotizing granu-
lomatous vasculitis or whether the two processes have developed
independently.
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